Recurrent skin reaction at the site of former subcutaneous injection after switching back to intravenous vedolizumab
Gastroenterol Hepatol. 2024 Apr;47(4):377-378.
doi: 10.1016/j.gastrohep.2023.06.006.
Epub 2023 Jul 1.
[Article in
English,
Spanish]
Affiliations
- 1 Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain; CIBEREHD, Spain.
- 2 Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.
- 3 Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain; CIBEREHD, Spain; Departament de Medicina, Universitat Autònoma de Barcelona, Spain. Electronic address: eugenidomenech@gmail.com.
No abstract available
MeSH terms
-
Administration, Intravenous
-
Antibodies, Monoclonal, Humanized* / adverse effects
-
Humans
-
Injections, Subcutaneous
Substances
-
vedolizumab
-
Antibodies, Monoclonal, Humanized